Santhera Pharmaceuticals Holding AG SANN

SWX: SANN | ISIN: CH0027148649   13/11/2024
8,420 CHF (-0,36%)
(-0,36%)   13/11/2024

12 november 2024 · Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar · Persbericht

1 oktober 2024 · Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism · Persbericht

24 september 2024 · Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy · Persbericht

12 september 2024 · Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update · Persbericht

10 september 2024 · Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe · Persbericht

13 augustus 2024 · Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026 · Persbericht

31 juli 2024 · Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary · Persbericht

18 juni 2024 · Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting · Persbericht

18 juni 2024 · Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even · Persbericht

10 juni 2024 · Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix · Persbericht

28 mei 2024 · Santhera Publishes Agenda for its Annual General Meeting · Persbericht

28 mei 2024 · Santhera Publishes Annual Report 2023 · Persbericht

25 april 2024 · Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May · Persbericht

27 maart 2024 · Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA · Persbericht

14 maart 2024 · Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States · Persbericht

14 februari 2024 · Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology · Persbericht

15 januari 2024 · Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy · Persbericht

12 januari 2024 · Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom · Persbericht

18 december 2023 · Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy · Persbericht

7 december 2023 · Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage · Persbericht

Mijn selecties